The actions of relaxin on the human cardiovascular system
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The insulin‐like peptide relaxin, originally identified as a hormone of pregnancy, is now known to exert a range of pleiotropic effects including vasodilatory, anti‐fibrotic, angiogenic, anti‐apoptotic and anti‐inflammatory effects in both males and females. Relaxin produces these effects by binding to a cognate receptor RXFP1 and activating a variety of signalling pathways including cAMP, cGMP and MAPKs as well as by altering gene expression of TGF‐β, MMPs, angiogenic growth factors and endothelin receptors. The peptide has been shown to be effective in halting or reversing many of the adverse effects including fibrosis in animal models of cardiovascular disease including ischaemia/reperfusion injury, myocardial infarction, hypertensive heart disease and cardiomyopathy. Relaxin given to humans is safe and produces favourable haemodynamic changes. Serelaxin, the recombinant form of relaxin, is now in extended phase III clinical trials for the treatment of acute heart failure. Previous clinical studies indicated that a 48 h infusion of relaxin improved 180 day mortality, yet the mechanism underlying this effect is not clear. This article provides an overview of the cellular mechanism of effects of relaxin and summarizes its beneficial actions in animal models and in the clinic. We also hypothesize potential mechanisms for the clinical efficacy of relaxin, identify current knowledge gaps and suggest new ways in which relaxin could be useful therapeutically. Linked Articles: This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564 · cited 1×
“Also, activation of the cGMP-PKG pathway is highly beneficial in many pathological cardiovascular states (Paulus and Tschope, 2013).”
BackgroundPeschel, T., Schönauer, M., Thiele, H., Anker, S., Schuler, G., & Niebauer, J. (2003) · European Journal of Heart Failure · doi:10.1016/s1388-9842(03)00104-1 · Cited by 187 · cited 4×
“In fact, in addition to these pivotal organs, there is also evidence for damage or malfunction of other organs such as intestine, lung and skeletal muscle, in the setting of ADHF (Peschel et al., 2003; Lauten et al., 2011; Hogan et al., 2012a,b).”
BackgroundInfluentialSarwar, M., Samuel, C. S., Bathgate, R. A., Stewart, D. R., & Summers, R. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12964 · Cited by 74 · cited 9×
“Signal transduction pathways activated by relaxin in vascular cells Relaxin given acutely causes cAMP, cGMP and pERK1/2 signalling in endothelial cells, VSMC and fibroblasts from human arteries and veins (Sarwar et al., 2015), mediated by Gαs, Gαi/o and GαOB G-proteins and involving PI3K downstream of G-protein activa…”
BackgroundSelf-citationRelaxin Treatment Reverses Insulin Resistance in Mice Fed a High-Fat Diet
Bonner, J. S., Lantier, L., Hocking, K. M., Kang, L., Owolabi, M., James, F. D., Bracy, D. P., Brophy, C. M., & Wasserman, D. H. (2013) · Diabetes · doi:10.2337/db13-0033 · Cited by 52 · cited 1×
“In mice with type 2 diabetes by highfat diet feeding for 13 weeks, relaxin administration over the last 3 weeks reduced fasting glucose level, improved insulin sensitivity, restored endothelial-dependent vasodilatation and reduced cardiac and hepatic fibrosis (Bonner et al., 2013).”
Background
Cited by
Mallart, S., Ingenito, R., Bianchi, E., Bresciani, A., Esposito, S., Gallo, M., Magotti, P., Monteagudo, E., Orsatti, L., Roversi, D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01533 · Cited by 29
Connolly, K., George, R., Omar, S., Matsson, E., Åstrand, M., Althage, M., Pettersen, D., Mohamed, E., Fang, K., Lima, J. A. C., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034067 · Cited by 13
Papworth, M., Kulkarni, S., Antonsson, M., Sermadiras, I., Hovdal, D., Connolly, K., Olsson, J., Shukla, A., Cotton, P., Althage, M., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf031 · Cited by 8
“13 Serelaxin, a recombinant relaxin-2 peptide, has been investigated previously as a potential therapy for acute decompensated HF. 14,15 Initial clinical trials with serelaxin demonstrated an acceptable safety profile and tolerability as well as improvements in dyspnoea after acute 48-h constant…”
Metadata
- Authors
- Sarwar, M., Du, X., Dschietzig, T. B., & Summers, R. J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2016-07-11
- Volume
- 174
- Issue
- 10
- Pages
- 933-949
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2409541478
- Cited by
- 104
- References
- 4
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The actions of relaxin on the human cardiovascular system. https://app.cochat.ai/papers/10.1111/bph.13523
- The paper
- Sarwar, M., Du, X., Dschietzig, T. B., & Summers, R. J. (2017). The actions of relaxin on the human cardiovascular system. British Journal of Pharmacology. https://doi.org/10.1111/bph.13523
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.